News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Release: Customizing Treatment With PEGASYS(R) May Improve Chances For Success In Hepatitis C



10/27/2006 11:11:57 AM

BOSTON--(BUSINESS WIRE)--Patients with chronic hepatitis C who respond quickly to PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin, USP) may have an excellent chance of achieving treatment success with a shortened course of therapy, according to interim results presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Three-quarters of patients with the difficult-to-treat viral genotypes 1 and 4 who had a rapid viral response (RVR) – defined as undetectable levels of the virus after four weeks of therapy – achieved treatment success after 24 weeks of therapy. (Patients with these genotypes are typically treated for 48 weeks.)

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES